Stocks with Implied Volatility Movement

Go back to Stocks with Implied Volatility Movement

Valeant Pharma (VRX) Reports Q1 Revenues Above Estimates; Boosts FY18 Revenue & EBITDA Outlook

May 8, 2018 7:05 AM EDT

Valeant Pharma (NYSE: VRX) reported Q1 EPS of ($7.68), versus $0.60 reported last year. Revenue for the quarter came in at $2 billion versus the consensus estimate of $1.95 billion.

Outperformed Expectations in the First Quarter of 2018Revenues of $1.995 BillionGAAP Net Loss of $2.693 BillionGAAP Cash Flow from... More